Reach Separations' strategic alliance with Evotec
REACH Separations has struck a strategic alliance with Evotec, which will see the UK-based company provide additional purification and analytical capability to support the German CRO's pharmaceutical clients worldwide.
As part of the deal, the chiral purification specialist will become a technology partner to Evotec and be responsible for providing expertise in small molecule chromatography.
The two companies have developed a working partnership since 2012, which provided a solid foundation for this official agreement.
The move was initiated by the CRO in a bid to support its expanded chemistry group by further improving the turnaround of chiral analysis and purification on client projects, without needing to make significant investment in additional equipment and facilities.
Located in BioCity in Nottingham, Reach Separations is capable of purifying from mg scale to in excess of 250g. It will now look after all chiral purification above 0.3g and 50% of all chiral analysis and purification under 0.3g for Evotec,
Reach Separations' technical group is led by Technical Director Phil Abbott, who has worked in the pharmaceutical industry for almost 20 years, including several years at AstraZeneca as a Separation Science Group Leader.
Phil said: "We are delighted to have struck a collaboration with one of the world's leading contract research organisations. Given the existing scientific knowledge available within the team at Evotec, this deal demonstrates the high level of purification and analytical expertise we are able to bring to such projects.
"As a result of this new partnership, we are already experiencing an increased workload. We have therefore invested in expanded laboratory space, taken on more scientists and also increased our instrumentation capability to ensure we are consistently delivering for Evotec and its clients."
Evotec is a drug discovery and development expert focused on rapidly progressing product approaches with pharmaceutical and biotechnology companies worldwide. Headquartered in Hamburg, the company has major operations in Abingdon, UK, Göttingen, Munich, Germany, San Francisco and Branford, USA.
Dave Hallett, executive vice president of discovery chemistry at Evotec, said: "The team at Reach Separations has considerable expertise in the fields of chiral, reverse phase and normal phase chromatography that will help our in-house team with added expertise and resource.
"By adding Reach Separations to our exclusive portfolio of technology partners, it will allow us to streamline our processes that will allow us to meet clients' project milestones even quicker."
The partnership is already well underway with the team at Reach Separations taking delivery of samples on a daily basis to support the Evotec chemistry group.
This is the latest strategic alliance for the team at Reach Separations, which has a strong track record in the pharmaceutical outsourcing sector. The company already works closely with chemistry expert Onyx Scientific, providing custom separation for companies in drug discovery and intermediate environments.
A big hello to....
Dave joins us from AstraZeneca where he was a Lead Chemist responsible for the manufacture and delivery of pharmaceutical drug substance for clinical and non-clinical studies across multiple disease areas within various cGMP facilities.
His experience in GxP and larger scale purifications add great value compliment the existing scientific team's skills here at Reach Separations and he has already completed a number of challenging separations projects.
You can contact Dave via his email - firstname.lastname@example.org, or you can reach all of our scientists at once via email@example.com